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Drugs used in the treatment of migraine have been
recently reported to be highly associated with the occur-
rence of clinically significant drug-drug interactions
(DDIs). The multiple drug therapy regimen is widely used
for migraine treatment, particularly for chronic migraine.
In fact, additional pharmacological agents are usually
administered during an acute migraine attack in patient
chronically treated with prophylactic therapy. The wide
variety of drugs available for migraine prophylactic and
acute treatment, and consequently their pharmacological
interactions, might complicate the choice of a safe combi-
nation therapy. The most frequently used drugs for the
prophylactic therapy of migraine belong to the antiepilep-
tic, b-blockers, tricyclic, SSRIs and SNRIs antidepressants
and antihistamine medications while acute migraine
attacks are treated with triptans, NSAIDs and ergot deriva-
tives. Moreover, in the last few years several of the latter
drugs have been combined in new formulations for clinical
use in order to improve treatment efficacy and, conse-
quently, the compliance of the patient. Drug-drug interac-
tions might occur at receptors level, both in the Central
Nervous System (CNS) and in the periphery, at the major
metabolic pathways levels (i.e., CYP450 enzymes) and at
the protein binding level. One of the most widely known
examples of the severity of such interactions is represented
by the serotoninergic syndrome induced by the co-admin-
istration of serotoninergic antidepressants and triptans.
In the management of chronic migraine, usually pro-
phylactic treatment is already administered, therefore
the choice of an additional drug for the acute attack
should be decided considering the specific DDIs.
Therefore, the aim of this study was to schematically
discuss the prophylactic-acute drug-drug interactions
from a pharmacokinetic and pharmacodynamic point of
view.
Authors’ details
1Advanced Molecular Diagnostics Unit, Sant’Andrea Hospital, Rome, Italy.
2Department of Clinical and Molecular Medicine, Sapienza University of
Rome, Rome, Italy. 3Regional Referral Headache Centre, Sant’Andrea Hospital,
Rome, Italy.
Published: 28 September 2015
doi:10.1186/1129-2377-16-S1-A36
Cite this article as: Lionetto and Martelletti: Choosing the safest acute
combination therapy during prophylactic treatment: pharmacokinetic
and pharmacodynamic considerations. The Journal of Headache and Pain
2015 16(Suppl 1):A36.
Submit your manuscript to a 
journal and benefi t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the fi eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com* Correspondence: luanalionetto@gmail.com
1Advanced Molecular Diagnostics Unit, Sant’Andrea Hospital, Rome, Italy
Full list of author information is available at the end of the article
Lionetto and Martelletti The Journal of Headache and Pain 2015, 16(Suppl 1):A36
http://www.thejournalofheadacheandpain.com/content/16/S1/A36
© 2015 Lionetto and Martelletti This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
